378 related articles for article (PubMed ID: 26428384)
21. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
Mautner J; Bornkamm GW
Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
[TBL] [Abstract][Full Text] [Related]
22. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
23. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
Huls MH; Rooney CM; Heslop HE
Acta Haematol; 2003; 110(2-3):149-53. PubMed ID: 14583675
[TBL] [Abstract][Full Text] [Related]
24. Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.
Smith C; Khanna R
Immunotherapy; 2015; 7(5):563-72. PubMed ID: 26065480
[TBL] [Abstract][Full Text] [Related]
25. Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
McLaughlin LP; Bollard CM; Keller MD
Front Immunol; 2018; 9():556. PubMed ID: 29616044
[TBL] [Abstract][Full Text] [Related]
26. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.
Heslop HE; Savoldo B; Rooney CM
Best Pract Res Clin Haematol; 2004 Sep; 17(3):401-13. PubMed ID: 15498712
[TBL] [Abstract][Full Text] [Related]
27. The Role of NK Cells in EBV Infection and EBV-Associated NPC.
Png YT; Yang AZY; Lee MY; Chua MJM; Lim CM
Viruses; 2021 Feb; 13(2):. PubMed ID: 33671917
[TBL] [Abstract][Full Text] [Related]
28. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
29. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
32. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
Ricciardelli I; Brewin J; Lugthart G; Albon SJ; Pule M; Amrolia PJ
Am J Transplant; 2013 Dec; 13(12):3244-52. PubMed ID: 24266973
[TBL] [Abstract][Full Text] [Related]
33. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.
Bollard CM; Savoldo B; Rooney CM; Heslop HE
Acta Haematol; 2003; 110(2-3):139-48. PubMed ID: 14583674
[TBL] [Abstract][Full Text] [Related]
34. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
[No Abstract] [Full Text] [Related]
35. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
36. EBV-associated lymphoproliferative disorders: classification and treatment.
Carbone A; Gloghini A; Dotti G
Oncologist; 2008 May; 13(5):577-85. PubMed ID: 18515742
[TBL] [Abstract][Full Text] [Related]
37. Rapid generation of Epstein-Barr virus-specific T cells for cellular therapy.
Hao QF; Yang YX; Wang Y; Chen LM; Sheng GY; Luan Z
Transplant Proc; 2014; 46(1):21-5. PubMed ID: 24507020
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; CarreƱo FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
39. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
Sharma S; Woods M; Mehta NU; Sauer T; Parikh KS; Schmuck-Henneresse M; Zhang H; Mehta B; Brenner MK; Heslop HE; Rooney CM
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072346
[TBL] [Abstract][Full Text] [Related]
40. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.
Heslop HE
Hematology Am Soc Hematol Educ Program; 2005; ():260-6. PubMed ID: 16304390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]